Sector in which the organization works:
Short description of the organization and its work to control and eliminate NTDs
The current insufficient supply of DEC has hindered global elimination efforts. As a global pharmaceutical company committed to improving health of all individuals worldwide, Eisai has decided to manufacture and supply DEC free of charge to WHO, facilitating achievement of the 2020 elimination target. Eisai will provide the WHO up to 2.2 billion 100mg tablets of DEC in accordance with WHO’s high quality standards over seven years beginning in 2013. Production of the medicine is planned at Eisai's Vizag Plant in India.
Eisai's global team for this program is currently preparing for the distribution of Eisai DEC and is working hand-in-hand with WHO to anticipate and address any challenges that might arise. The company is also working with the Global Alliance to Eliminate Lymphatic Filariasis (GAELF) and the Global Network for Neglected Tropical Diseases (GNNTD) to ensure effective elimination of lymphatic filariasis worldwide. This should result in 2.2 billion doses being distributed through via WHO (2013-20) and helping 200 million people receive treatment to prevent them suffering from Lymphatic filariasis.
Eisai began manufacturing and supplying 2.2 billion tablets of DEC to WHO in late 2013. To ensure a stable of supply of DEC until the Eisai-produced DEC becomes available, Eisai, Sanofi and the Bill & Melinda Gates Foundation have committed to provide 120 million DEC tablets manufactured by Sanofi to the WHO free of charge. This is the first partnership in which two pharmaceutical companies, with the Bill & Melinda Gates Foundation, have come together to supply a single drug for an NTD.
Eisai is one of the 20 original endorsers of the London Declaration
Lymphatic Filariasis Elimination Partnership